Robert M Bober1,2, Richard V Milani3,4, Selim R Krim3,4, Daniel P Morin3,4. 1. Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, 1514 Jefferson Highway, New Orleans, LA, 70121-2483, USA. rbober@ochsner.org. 2. Ochsner Clinical School, Queensland University School of Medicine, New Orleans, LA, USA. rbober@ochsner.org. 3. Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, 1514 Jefferson Highway, New Orleans, LA, 70121-2483, USA. 4. Ochsner Clinical School, Queensland University School of Medicine, New Orleans, LA, USA.
Abstract
PURPOSE OF REVIEW: Cardiomyopathy with underlying left ventricular (LV) dysfunction is a heterogenous group of disorders that may be present with, and/or secondary to, coronary artery disease (CAD). The purpose of this review is to demonstrate, via case illustrations, the benefits offered by cardiac positron-emission tomography (PET) stress testing with coronary flow capacity (CFC) in the evaluation and treatment of patients with left ventricular (LV) dysfunction and CAD. RECENT FINDINGS: CFC, a metric that is increasing in prominence, represents the integration of several absolute perfusion metrics into clinical strata of CAD severity. Our prior work has demonstrated improvement in regional perfusion metrics as a result of revascularization to territories with severe reduction in CFC. Conversely, when CFC is adequate, there is no change in regional perfusion metrics following revascularization, despite angiographically severe stenosis. Furthermore, Gould et al. demonstrated decreased rates of myocardial infarction and death following revascularization of myocardium with severely reduced CFC, with no clinical benefit observed following revascularization of patients with preserved CFC. In a series of cases, we present pre-revascularization and post-revascularization PET scans with perfusion metrics in patients with LV dysfunction and CAD. In these examples, we demonstrate improvement in LV function and perfusion metrics following revascularization only in cases where baseline CFC is severely reduced. PET with CFC offers unique guidance regarding revascularization in patients with reduced LV function and CAD.
PURPOSE OF REVIEW: Cardiomyopathy with underlying left ventricular (LV) dysfunction is a heterogenous group of disorders that may be present with, and/or secondary to, coronary artery disease (CAD). The purpose of this review is to demonstrate, via case illustrations, the benefits offered by cardiac positron-emission tomography (PET) stress testing with coronary flow capacity (CFC) in the evaluation and treatment of patients with left ventricular (LV) dysfunction and CAD. RECENT FINDINGS: CFC, a metric that is increasing in prominence, represents the integration of several absolute perfusion metrics into clinical strata of CAD severity. Our prior work has demonstrated improvement in regional perfusion metrics as a result of revascularization to territories with severe reduction in CFC. Conversely, when CFC is adequate, there is no change in regional perfusion metrics following revascularization, despite angiographically severe stenosis. Furthermore, Gould et al. demonstrated decreased rates of myocardial infarction and death following revascularization of myocardium with severely reduced CFC, with no clinical benefit observed following revascularization of patients with preserved CFC. In a series of cases, we present pre-revascularization and post-revascularization PET scans with perfusion metrics in patients with LV dysfunction and CAD. In these examples, we demonstrate improvement in LV function and perfusion metrics following revascularization only in cases where baseline CFC is severely reduced. PET with CFC offers unique guidance regarding revascularization in patients with reduced LV function and CAD.
Authors: L David Hillis; Peter K Smith; Jeffrey L Anderson; John A Bittl; Charles R Bridges; John G Byrne; Joaquin E Cigarroa; Verdi J Disesa; Loren F Hiratzka; Adolph M Hutter; Michael E Jessen; Ellen C Keeley; Stephen J Lahey; Richard A Lange; Martin J London; Michael J Mack; Manesh R Patel; John D Puskas; Joseph F Sabik; Ola Selnes; David M Shahian; Jeffrey C Trost; Michael D Winniford Journal: J Am Coll Cardiol Date: 2011-11-07 Impact factor: 24.094
Authors: K Lance Gould; Nils P Johnson; Timothy M Bateman; Rob S Beanlands; Frank M Bengel; Robert Bober; Paolo G Camici; Manuel D Cerqueira; Benjamin J W Chow; Marcelo F Di Carli; Sharmila Dorbala; Henry Gewirtz; Robert J Gropler; Philipp A Kaufmann; Paul Knaapen; Juhani Knuuti; Michael E Merhige; K Peter Rentrop; Terrence D Ruddy; Heinrich R Schelbert; Thomas H Schindler; Markus Schwaiger; Stefano Sdringola; John Vitarello; Kim A Williams; Donald Gordon; Vasken Dilsizian; Jagat Narula Journal: J Am Coll Cardiol Date: 2013-08-28 Impact factor: 24.094
Authors: Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young Journal: Circulation Date: 2006-03-27 Impact factor: 29.690
Authors: Danai Kitkungvan; Nils P Johnson; Amanda E Roby; Monika B Patel; Richard Kirkeeide; K Lance Gould Journal: JACC Cardiovasc Imaging Date: 2016-12-21
Authors: Mark C Petrie; Pardeep S Jhund; Lilin She; Christopher Adlbrecht; Torsten Doenst; Julio A Panza; James A Hill; Kerry L Lee; Jean L Rouleau; David L Prior; Imtiaz S Ali; Jyotsna Maddury; Krzysztof S Golba; Harvey D White; Peter Carson; Lukasz Chrzanowski; Alexander Romanov; Alan B Miller; Eric J Velazquez Journal: Circulation Date: 2016-08-29 Impact factor: 29.690